SCHEMBL3297481

SCHEMBL3297481

CC(C)(C)C(=O)Nc1cnc(C(=O)CBr)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KDR P35968 2/20 0.36
RAB9A P51151 5/20 0.35
NPC1 O15118 4/20 0.35
PAX8 Q06710 1/20 0.35
KLF5 Q13887 1/20 0.35
ABL1 P00519 1/20 0.34
GRIN2B Q13224 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ADORA1 P30542 1/20 0.34
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1445413 0.86 CNR2 (0.39) CNR2L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL3290978 0.85 KDR (0.38) CNR2L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL1445808 0.81 CNR2 (0.36) CNR2L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL2644678 0.81 L3MBTL1 (0.41) CNR2L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL3291100 0.80 CCNB2 (0.36) CNR2L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL3290355 0.80 NPC1 (0.36) CNR2L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL3293626 0.78 MAPK1 (0.44) CNR2L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL1445669 0.78 CNR2 (0.34) CNR2L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL1445667 0.76 L3MBTL1 (0.42) CNR2L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL15759482 0.72 GSK3B (0.40) CYP2C19RAB9ANPC1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727750-B2 Biocatalytic asymmetric reduction in preparation of (S)-N-[5-(1,2-dihydroxy-ethyl)-pyrazinyl]-2,2-dimethyl-propionamide HOFFMAN-LA ROCHE INC. (US) 2010-06-01 US disclosed
US-7727750-B2 Biocatalytic asymmetric reduction in preparation of (S)-N-[5-(1,2-dihydroxy-ethyl)-pyrazinyl]-2,2-dimethyl-propionamide HOFFMAN-LA ROCHE INC. (US) 2010-06-01 US disclosed
US-7727750-B2 Biocatalytic asymmetric reduction in preparation of (S)-N-[5-(1,2-dihydroxy-ethyl)-pyrazinyl]-2,2-dimethyl-propionamide HOFFMAN-LA ROCHE INC. (US) 2010-06-01 US disclosed
EP-2145012-A2 MICROBIAL REDUCTION OF AN ACETOXYKETONE F. Hoffmann-Roche AG (CH) 2010-01-20 EP disclosed
WO-2008122511-A2 PROCESS FOR PREPARING 2-AMINO- [5-(1(S), 2-DIHYDROXYETHYL) OR - (KS) -HYDROXY-2-HALOETHYL) ] -PYRAZINE DERIVATIVES BY ENZYMATIC REDUCTION OF THE CORRESPONDING KETONES F. HOFFMANN-LA ROCHE AG (CH) 2008-10-16 WO disclosed
WO-2008122511-A2 PROCESS FOR PREPARING 2-AMINO- [5-(1(S), 2-DIHYDROXYETHYL) OR - (KS) -HYDROXY-2-HALOETHYL) ] -PYRAZINE DERIVATIVES BY ENZYMATIC REDUCTION OF THE CORRESPONDING KETONES F. HOFFMANN-LA ROCHE AG (CH) 2008-10-16 WO disclosed
US-20080248537-A1 BIOCATALYTIC ASYMMETRIC REDUCTION IN PREPARATION OF (S)-N-[5-(1,2-DIHYDROXY-ETHYL)-PYRAZINYL]-2,2-DIMETHYL-PROPIONAMIDE F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 US disclosed
US-20080248537-A1 BIOCATALYTIC ASYMMETRIC REDUCTION IN PREPARATION OF (S)-N-[5-(1,2-DIHYDROXY-ETHYL)-PYRAZINYL]-2,2-DIMETHYL-PROPIONAMIDE F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 US disclosed
US-20080248537-A1 BIOCATALYTIC ASYMMETRIC REDUCTION IN PREPARATION OF (S)-N-[5-(1,2-DIHYDROXY-ETHYL)-PYRAZINYL]-2,2-DIMETHYL-PROPIONAMIDE F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080248537-A1 BIOCATALYTIC ASYMMETRIC REDUCTION IN PREPARATION OF (S)-N-[5-(1,2-DIHYDROXY-ETHYL)-PYRAZINYL]-2,2-DIMETHYL-PROPIONAMIDE GCK, HK2, GCKR CNR2 1743/4885L3MBTL1 3788/4885CYP1A2 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.